BMS’ Breyanzi recived positive CHMP Opinion for Hematologic malignancy

BMS reported updated results for Nivolumab in Neoadjuvant NSCLC

Transcenta received Orphan Drug Designation for Osemitamab to treat Pancreatic cancer

Keytruda in combination with chemo, significantly reduced the risk of progression in Endometrial cancer

Kisqali showed encouraging results in HR+/HER2- Early Breast Cancer patients

Incyte’s Pemazyre received Japan approval to treat Myeloid/Lymphoid Neoplasms